Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Appeals Court Says Rituxan, Avastin Do Not Infringe Sanofi Patents

3/22/2012 11:12 PM ET

An appeals court on Thursday upheld a lower court's ruling that the cancer drugs Rituxan and Avastin of Swiss drug maker Roche Holding AG's (RHHBY.PK) Genentech unit and biotechnology firm Biogen Idec Inc. (BIIB: Quote) do not infringe two patents of French drug maker Sanofi SA (SNY: Quote,SNYNF.PK).

Genentech's Avastin, which had sales of 5.29 billion Swiss francs in 2011, is a blockbuster drug for treatment of cancers related to colon, lung, kidney and brain. Rituxan had sales of 6.01 billion Swiss francs in 2011. Rituxan is currently co-marketed by Biogen Idec and Genentech in the U.S.

In a ruling posted on the court's website, the U.S. Court of Appeals for the Federal Circuit said that Sanofi's '522 and '140 patents were not infringed by Genentech and Biogen. The court ruled that the district court had not erred in its judgment.

In October 2008, Sanofi filed a lawsuit for infringement of the two patents, alleging that Genentech and Biogen made use of an infringing enhancer in producing the antibody-based drugs Rituxan and Avastin.

SNY closed Thursday's trading at $38.45, down $0.23 or 0.59 percent on a volume of 1.86 million shares.

Click here to receive FREE breaking news email alerts for Sanofi and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
While Republicans will try to use the troubled rollout of Obamacare to their advantage in the upcoming midterm elections, the results of a Reuters/Ipsos poll showed that Americans increasingly think Democrats have a better plan for healthcare. Nearly three hundred people are still unaccounted for after a ferry carrying 462 people capsized and sank off South Korea's southern coast, media reports citing local officials said Wednesday. The ill-fated ferry, carrying mostly high school students on an overnight trip, was heading to the tourist island of Jeju from the city of Incheon, a northwestern South Korean city that houses the country's After moving mostly higher in early trading on Wednesday, stocks have continued to perform well over the course of the session. While buying interest has waned since then open, the markets have maintained a positive bias on the day.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.